Archives20242023202220212020201920182017201620152014201320122011 July 16, 2021BOARD APPOINTMENT Read More June 28, 20212021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED Read More June 24, 2021FDA to agree on the Lupzuor™ PK study via a written response to “Type Read More June 02, 2021Notice of AGM and posting of Report & Accounts Read More May 24, 2021Director Retirement Read More April 29, 2021FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020 Read More February 09, 2021Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More January 18, 2021Appointment of Company Secretary Read More January 04, 2021Lanstead Capital TR1 Read More December 03, 2020ImmuPharma to present at Biotech Showcase™ Digital 2021 Read More November 30, 2020Total Share Capital Notification Read More November 26, 2020Grant of Share Options & PDMR dealing Read More 1…56789…21
February 09, 2021Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More